A Phase 2/3 interventional study of Treprostinil Palmitil and Placebo in Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated. Active, not recruiting at 45 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Insmed Incorporated · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.
Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 73rd largest by enrollment of the 253 interventional ones that give a count, is one of 16 that started in 2023, is one of 5 in phase 2/3, reaches primary completion later than 15 of the 55 other live ones, and was the 271st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States, Spain, United Kingdom
Ages 18+
Insmed Incorporated · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 73 · Phase 4 33
First in 2002; this study’s year is marked. 16 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 40 across the 253 interventional studies, 67 across the 59 observational. Of the 235 that completed or were terminated, 133 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 312 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 5 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Pulmonary Arterial Hypertension with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07312227Massachusetts General HospitalA Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are not transitioning immediately from other TPIP studies:INS1009-201(NCT04791514), INS1009-202(NCT05147805) and other lead-in studies, will be given TPIP, once daily (QD), starting with 80 micrograms (μg), up-titrated to highest tolerated dose between 80 μg and 640 μg during 3-week titration period that maybe increased upto maximum dose of 1280 μg QD post initial titration, per investigator's assessment. Overall treatment period=24 months. Participants transitioning immediately from randomized blinded lead-in TPIP study and who previously received: 1. TPIP- will be given placebo QD(80 μg upto achieved TPIP dose from previous study)along with achieved TPIP dose from previous study in blinded manner during 3-week titration period. 2. Placebo- will be given TPIP QD (80 μg up to achieved placebo dose from previous study)along with achieved placebo dose from previous study in blinded manner during 3-week titration period.Overall treatment period=24 months.
Drug: Treprostinil Palmitil · Drug: Placebo
Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
Also known as: INS1009
Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity
Time frame: From screening up to last follow up visit (Up to approximately 26 months)
Absolute Change From Pre-Open Label Extension (OLE) Baseline in 6-Minute Walk Distance (6MWD)
Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
Relative Change From Pre-OLE Baseline in 6MWD
Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in the Concentration of N-Terminal Fragment B-Type Natriuretic Peptide (NT-proBNP) in Blood
Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Score
Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in New York Heart Association/ World Health Organization (NYHA/WHO) Functional Capacity Class
Time frame: Pre-OLE baseline (baseline of the lead-in TPIP study), Months 6, 12, 18, and 24
Annualized Clinical Worsening Event Rate
Annualized clinical worsening event rate is defined as the total number of clinical worsening events that occurred during the treatment period divided by the total number of participant-years during the treatment period. Clinical worsening events are one of the following: All-cause death, or onset of TEAE with a fatal outcome occurring ≤ 14 days after study drug discontinuation; Hospitalization for right heart failure (for \> 48 hours), heart-lung or lung transplant, or atrial septostomy; Addition (or increase in dose) of specified PAH-specific medications; Combined occurrence of events including ≥20% decrease in 6MWD, worsening WHO/NYHA functional capacity class, and appearance of or worsening of signs/symptoms of right heart failure from baseline.
Time frame: OLE Baseline (Day 1) up to Month 24 or early discontinuation
Plasma Concentration Levels of Treprostinil Palmitil (TP) and Treprostinil (TRE)
Time frame: OLE Baseline (Day 1), Months 6, 12, 18, and 24
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil hexadecyl ester
Pulmonary Arterial Hypertension →